Immix Biopharma Independent Director Acquires 2.6% More Stock

Simply Wall St.08-29

Even if it's not a huge purchase, we think it was good to see that Jason Hsu, the Independent Director of Immix Biopharma, Inc. (NASDAQ:IMMX) recently shelled out US$52k to buy stock, at US$2.23 per ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2463255739?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","is_english":true,"pubTime":"2024-08-29 20:49","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2463255739","market":"us","top_or_hot":-1,"title":"Immix Biopharma Independent Director Acquires 2.6% More Stock","media":"Simply Wall St.","content":"<div>\n<p>Even if it's not a huge purchase, we think it was good to see that Jason Hsu, the Independent Director of Immix Biopharma, Inc. (NASDAQ:IMMX) recently shelled out US$52k to buy stock, at US$2.23 per ...</p>\n\n<a href=\"https://finance.yahoo.com/news/immix-biopharma-independent-director-acquires-124901553.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immix Biopharma Independent Director Acquires 2.6% More Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmix Biopharma Independent Director Acquires 2.6% More Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-29 20:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/immix-biopharma-independent-director-acquires-124901553.html><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Even if it's not a huge purchase, we think it was good to see that Jason Hsu, the Independent Director of Immix Biopharma, Inc. (NASDAQ:IMMX) recently shelled out US$52k to buy stock, at US$2.23 per ...</p>\n\n<a href=\"https://finance.yahoo.com/news/immix-biopharma-independent-director-acquires-124901553.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMMX","symbol_name":"Immix Biopharma, Inc","start_time":0,"source_url":"https://finance.yahoo.com/news/immix-biopharma-independent-director-acquires-124901553.html","article_id":"2463255739","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2463255739","pubTimestamp":1724935741,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Even if it's not a huge purchase, we think it was good to see that Jason Hsu, the Independent Director of Immix Biopharma, Inc.  recently shelled out US$52k to buy stock, at US$2.23 per share. Although the purchase is not a big one, increasing their shareholding by only 2.6%, it can be interpreted as a good sign.In fact, the recent purchase by Independent Director Jason Hsu was not their only acquisition of Immix Biopharma shares this year. They previously made an even bigger purchase of US$267k worth of shares at a price of US$4.88 per share. So it's clear an insider wanted to buy, even at a higher price than the current share price . Their view may have changed since then, but at least it shows they felt optimistic at the time. We always take careful note of the price insiders pay when purchasing shares. As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a hi","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMMX":"Immix Biopharma, Inc","BK4139":"生物科技"},"translate_title":"Immix Biopharma独立董事增持2.6%股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMMX":0.9},"content_text":"Even if it's not a huge purchase, we think it was good to see that Jason Hsu, the Independent Director of Immix Biopharma, Inc. (NASDAQ:IMMX) recently shelled out US$52k to buy stock, at US$2.23 per share. Although the purchase is not a big one, increasing their shareholding by only 2.6%, it can be interpreted as a good sign. \n See our latest analysis for Immix Biopharma \n The Last 12 Months Of Insider Transactions At Immix Biopharma \n In fact, the recent purchase by Independent Director Jason Hsu was not their only acquisition of Immix Biopharma shares this year. They previously made an even bigger purchase of US$267k worth of shares at a price of US$4.88 per share. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$2.22). Their view may have changed since then, but at least it shows they felt optimistic at the time. We always take careful note of the price insiders pay when purchasing shares. As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. \n While Immix Biopharma insiders bought shares during the last year, they didn't sell. They paid about US$3.03 on average. These transactions suggest that insiders have considered the current price attractive. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction! \n\n\n\n  NasdaqCM:IMMX Insider Trading Volume August 29th 2024\n \n\n There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying. \n Insider Ownership \n For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. Insiders own 28% of Immix Biopharma shares, worth about US$17m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders. \n So What Does This Data Suggest About Immix Biopharma Insiders? \n The recent insider purchases are heartening. And an analysis of the transactions over the last year also gives us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. Given that insiders also own a fair bit of Immix Biopharma we think they are probably pretty confident of a bright future. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Case in point: We've spotted 6 warning signs for Immix Biopharma you should be aware of, and 3 of them are concerning. \n But note: Immix Biopharma may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt. \nFor the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.\nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2463255739"}